Clinical trials
Phase 1 Leukemia, Myeloid, Acute trials in Australia
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
53 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2006 | 1 |
| 2010 | 2 |
| 2012 | 1 |
| 2013 | 1 |
| 2014 | 4 |
| 2015 | 2 |
| 2016 | 2 |
| 2017 | 7 |
| 2018 | 7 |
| 2019 | 3 |
| 2020 | 5 |
| 2021 | 2 |
| 2022 | 5 |
| 2023 | 4 |
| 2024 | 5 |
| 2025 | 1 |
| 2026 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 18 |
| Terminated | 16 |
| Unknown status | 6 |
| Active, not recruiting | 6 |
| Recruiting | 5 |
| Enrolling by invitation | 1 |
| Withdrawn | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| AbbVie | 8 |
| Amgen | 4 |
| Institut de Recherches Internationales Servier | 4 |
| Novartis Pharmaceuticals | 4 |
| Janssen Research & Development, LLC | 3 |
| CSL Limited | 2 |
| Celgene | 2 |
| Hoffmann-La Roche | 2 |
| University of Sydney | 2 |
| Allotera Therapeutics | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Leukemia, Myeloid, Acute | 53 |
| Myelodysplastic Syndromes | 17 |
| Recurrence | 9 |
| Lymphoma, Non-Hodgkin | 8 |
| Leukemia | 7 |
| Multiple Myeloma | 6 |
| Neoplasms | 6 |
| Leukemia, Myelomonocytic, Chronic | 5 |
| Leukemia, Lymphocytic, Chronic, B-Cell | 4 |
| Leukemia, Myeloid | 2 |
Trials
Showing 1 to 25 of 53. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.